P3 Health Partners Inc. (PIII)
SubavaliadaFundamental
30
Preço
$6.74
Capitalização de Mercado
$1.38B
Parte 1 · Quanto vale a empresa
Visão Geral
P3 Health Partners is a physician-led population health company that helps primary care doctors take financial responsibility for the total cost of care of their Medicare Advantage patients. It does not own the insurance plan and it is not primarily a clinic operator: it sits between health plans and affiliated physician practices, supplying the data, care-management staff, risk-adjustment workflows and shared-savings economics that let independent doctors work under value-based contracts. In fiscal 2025 the company served roughly 116,000 at-risk members across markets including Nevada, Arizona, California, Oregon and Florida, working with a network of about 2,400 primary care physicians — fewer than 1% of the primary care doctors in the United States. It reached the public market in December 2021 through a merger with the SPAC Foresight Acquisition Corp. and is organised as an 'Up-C': the listed entity P3 Health Partners Inc. owned about 46% of the operating company P3 Health Group, LLC at the end of 2025. The 10-K filed in March 2026 states that management concluded there is substantial doubt about the company's ability to continue as a going concern.
Como gera receita
Almost all revenue is capitated: health plans pay P3 a fixed per-member-per-month amount for each Medicare Advantage member assigned to its physicians, and P3 keeps whatever is left after paying for that member's medical care. The spread between the premium received and the claims incurred is what the company calls medical margin; the plan's own risk-adjustment and quality (Stars) performance feeds directly into the monthly rate, so documenting patients' conditions accurately is part of the revenue engine rather than back-office work. Smaller streams come from clinical fees, care-coordination management fees and quality incentive payments. The model means P3 carries insurance-like risk without insurance-like scale: in fiscal 2025 total revenue was $1.46 billion on roughly 116,000 at-risk members, capitated revenue was $1,026 per member per month, and medical margin was only $23.5 million — $17 per member per month — against a net loss of $323.1 million.
Vantagem competitiva
Nenhuma vantagem identificada · NenhumaP3 reports as a single business and has not shown a durable advantage in it. Its physician relationships are contractual and its payor relationships are renegotiated periodically; the same value-based enablement service is offered by much larger and better-capitalised rivals, and the health plans themselves increasingly build the capability in-house. The economics show the absence plainly: after several years of operation the company earned $17 per member per month of medical margin in 2025 and lost $323.1 million, while at-risk membership fell about 8% as it exited contracts that did not work. A company that cannot hold price or volume on its own terms, and that depends on continued access to capital to keep operating, is not being protected by anything structural.
O que impulsiona a procura
Moderadamente cíclicoThe underlying need — medical care for people over 65 — does not follow the economic cycle, and Medicare Advantage enrolment has grown for years with the ageing of the population. What moves P3's results is not consumer demand but the policy and contracting cycle: annual CMS rate notices, risk-adjustment rules, the medical cost trend (how much care members actually use), and the terms it can win when payor contracts come up for renewal. Those swings are large enough to overwhelm the steady demographic pull: membership fell about 8% in 2025 because the company deliberately exited misaligned contracts, and revenue slipped from $1.50 billion to $1.46 billion even as per-member capitation rose 5%.
Principais riscos
- Going concern and the need for new capital — The company states that substantial doubt exists about its ability to continue as a going concern. It ended 2025 with $25.0 million of unrestricted cash against $336.7 million of debt ($45.0 million of it current) and $287.8 million of unpaid claims, an accumulated deficit of $651.1 million, and it expects to need additional funding during 2026. Financing so far has included $18.0 million from a related party.
- Dependence on a handful of health plans — Contracts with four health plans accounted for approximately 75% of total revenue in 2025, up from approximately 59% in 2024. The filing warns that losing or failing to renew a major Medicare Advantage contract, or a deterioration in a plan's own quality ratings, would directly hit revenue.
- Reimbursement and healthcare spending policy — Revenue depends on Medicare Advantage reimbursement, which is set by government policy and by health plan contracting. The company lists changes in healthcare spending and legislation, and the terminability of Medicare Advantage contracts, among its principal risks.
- Heavy healthcare regulation and government audits — The filing cites the complexity of compliance with anti-kickback, fraud and abuse rules and corporate-practice-of-medicine restrictions, along with exposure to government audits and investigations. It also flags data protection and privacy obligations and emerging regulation of artificial intelligence.
- Debt covenants and regulatory capital at subsidiaries — The company identifies the risk of failing to comply with the covenants on its debt, and notes regulatory capital pressure in California, where its Medcore HP entity fell below the required tangible net equity.
- Holding-company structure and Nasdaq listing — P3 Health Partners Inc. is a holding company whose main asset is a roughly 46% interest in P3 Health Group, LLC, so public shareholders hold a minority claim on the operating business; the company also carries obligations under a Tax Receivable Agreement. Compliance with Nasdaq listing requirements is listed as a risk.
Concentração de clientes
Os principais clientes representam 75% da receita
Contracts with four health plans provided approximately 75% of total revenue in fiscal 2025, against approximately 59% from four plans in fiscal 2024 — concentration rose sharply as the company shrank its book. P3's customers are the insurers, not the patients: a single renegotiation or non-renewal can move a large share of the top line, and the counterparties are far larger than P3.
Os argumentos a favor
Buyers argue that the company has stopped growing for growth's sake and is now fixing the unit economics: it walked away from about 8% of its at-risk members in 2025 to shed contracts that could not pay, lifted capitated revenue per member per month 5% to $1,026, and cut its normalised Adjusted EBITDA loss from $193.0 million to $149.1 million. Management guides 2026 Adjusted EBITDA to a range of negative $20 million to positive $40 million, a midpoint that would be roughly $170 million better than 2025, on revenue of $1.5–1.7 billion and 107,000–117,000 at-risk members. On that view, a physician-led platform with only about 2,400 primary care doctors under contract — under 1% of the US total — still has a very long runway if the model reaches break-even, and the demographic shift into Medicare Advantage keeps the addressable pool expanding.
Os argumentos contra
Sellers fear that the clock runs out before the model works. The company itself says substantial doubt exists about its ability to continue as a going concern: it entered 2026 with $25.0 million of unrestricted cash against $336.7 million of debt and $287.8 million of unpaid claims, an accumulated deficit of $651.1 million, and an explicit expectation of needing more capital — capital that, for a business losing $323.1 million a year, tends to come at a heavy cost to existing shareholders. They also point out that the improvement story rests on a very thin cushion: $17 of medical margin per member per month leaves no room for an adverse cost trend, one bad flu season or one unfavourable rate notice. Meanwhile 75% of revenue sits with four health plans that are far larger counterparties, membership is shrinking rather than growing, and public shareholders own a holding company that holds only about 46% of the operating business and carries Tax Receivable Agreement obligations on top.
Generated on 19 de setembro de 2026 with claude-haiku-4-5 — shared with all users
Direct competitors
Who this company fights with for the same customers
Generated on 19 de setembro de 2026 with claude-haiku-4-5 — shared with all users
Privia competes for the same prize — the affiliation of independent physician groups — offering them a national platform and value-based contracts instead of joining a network like P3's.
Through Optum Health, UnitedHealth employs and affiliates primary-care physicians in P3's states and manages their Medicare Advantage patients itself, taking both the doctors and the capitated revenue P3 is competing for.
Named by P3 in its own 10-K: agilon signs the same independent primary-care groups to full-risk Medicare Advantage contracts, so the two bid for the same physician partners and the same senior patients.
Also named by P3 in its 10-K: Astrana runs risk-bearing physician networks paid by capitation in California and the Southwest, overlapping directly with P3's markets in California, Nevada and Arizona.
The third competitor P3 names: Aledade recruits independent primary-care practices into shared-savings and value-based contracts with the same Medicare and Medicare Advantage payors P3 depends on.
Balanço & Liquidez
Receita
$1.50B
Últimos 12 meses (até 30/06/2026)
Resultado Líquido
$-98M
Últimos 12 meses (até 30/06/2026)
Fluxo de Caixa Livre
-
Capital Próprio Total
$-155M
Passivo Total
$797M
Rácio de Liquidez
0.46
Cobertura de Juros
2.44
Dívida/EBITDA
-
Resultados Por Ação
Receita & Resultado Líquido
Fluxo de Caixa Livre
Decomposição dos Resultados
Demonstração histórica
Margens ao longo do tempo
A dívida ao longo do tempo
Quanto pesa a dívida
Grelha do crescimento
Crescimento — Receitas
Estimativa de Valor Justo
Valor Justo
$18.00
Preço Atual
$6.74
Margem de Segurança
+62.6%
Intervalo de Valor Justo
$17.10 - $18.90
Dispersão entre os métodos de avaliação utilizados, não um intervalo de confiança calibrado estatisticamente.
Métodos de Estimativa
Métricas de Avaliação
Rácio P/E
-
ROE
95.3%
Rácio P/B
-
P/FCF
-
Margem Bruta
-
ROIC
-44.2%
Radar de Rentabilidade
Criação de Valor (Vantagem Competitiva)
ROIC
-44.2%
WACC
14.9%
ROIC − WACC
-59.1 pp
O ROIC está abaixo do custo do capital — a empresa está a destruir valor a cada dólar investido.
Critérios de Análise Fundamental
Aprovado (5)
- Interest Coverage
- ROE 10.3%
- Revenue Growth 5Y 24.6%
- Analyst Consensus 75% Buy
- Net Margin Trend -6.6% vs -10.0%
Reprovado (11)
- EPS shows upward trend
- Price CAGR -54.21%
- ROIC -44.2%
- Operating Margin -9.9%
- Current Ratio
- Return on Tangible Assets
- Low reliance on intangibles
- DCF valuation (Unknown)
- Earnings Surprise avg -4.8%
- Share Dilution 30.1%
- Piotroski F-Score 2/9
Indisponível (11)
- Gross Margin NaN%
- P/FCF NaN
- P/B Ratio NaN
- Dividend Payout NaN%
- Debt/Equity ratio
- Positive Free Cash Flow
- CapEx intensity
- Debt/EBITDA
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-Score
Preocupações financeiras graves
Qualidade dos Resultados
Baixa qualidade: investigar a contabilidade
Diluição de Ações
A emitir novas ações, diluindo a participação
Participações institucionais
Governação
Equipa Executiva
| Nome | Cargo | Idade |
|---|---|---|
| Dr. Aric Coffman M.D. | CEO, President & Director | 51 |
| Dr. Amir Bacchus M.B.A., M.D. | Co-Founder, Chief Medical Officer & Director | 60 |
| Mr. Leif Pedersen | Chief Financial Officer | 49 |
| Mr. William Bettermann | Executive VP & COO | - |
| Mr. Devery Goodey | Senior Vice President of Technology | - |
| Ms. Sarah Bussmann B.S.N., CRNI, M.H.A., R.N. | Chief Administrative Officer | - |
| Mr. William Hoover | Investor Relations Officer | - |
| Mr. Todd M. Smith | Chief Legal Officer, Chief Compliance Officer & Corporate Secretary | - |
| Ms. Kassi Belz APR | Executive Vice President of Marketing & Communications | - |
| Ms. Shelly Martin | Regional President of Nevada & Arizona | - |
Parte 2 · O preço e o momento de entrar
Esta parte não serve para saber se a empresa vale: serve para escolher quando comprá-la, depois que os fundamentos te convenceram. Dentro: análise técnica, potencial, quedas históricas, exposição gama.
Documentos
- Ver documento
Relatório anual (10-K)
Uma visão anual do negócio, dos resultados financeiros e dos riscos da empresa.
Arquivado em 2026-03-26
- Ver documento
Relatório trimestral (10-Q)
Uma atualização sobre o desempenho financeiro dos últimos três meses.
Arquivado em 2026-08-10
- Ver documento
Relatório de fato relevante (8-K)
Um aviso sobre um fato relevante, como uma mudança na liderança ou um grande anúncio.
Arquivado em 2026-09-11
via SEC EDGAR
Histórico de Resultados
via SEC EDGAR
Latest News
Recent headlines for PIII, sourced from Markets Gazette.